New pill aims to tame stubborn blood cancers in early trial

NCT ID NCT06980116

Recruiting now Disease control Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Dec 26, 2025 · Last updated May 23, 2026 · Updated 17 times

Summary

This early-phase study tests an experimental oral drug, EXS73565, in about 50 adults with certain B-cell blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard therapy. The main goals are to check the drug's safety and find the right dose. Researchers will also watch for any signs that the drug shrinks or controls the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital Fundación Jiménez Diaz
RECRUITING

Madrid, Spain
Hospital Universitario HM Sanchinarro
RECRUITING

Madrid, Spain
St James's University Hospital
RECRUITING

Leeds, United Kingdom
University Hospitals Plymouth NHS Trust
RECRUITING

Plymouth, United Kingdom

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY B-CELL MALIGNANCIES